Cancer. A bull's eye for targeted lung cancer therapy.
Minna
John D
JD
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. john.minna@utsouthwestern.edu
Gazdar
Adi F
AF
Sprang
Stephen R
SR
Herz
Joachim
J
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D019943:Amino Acid Substitution; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D018849:Controlled Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D000077156:Gefitinib; D018773:Genes, erbB-1; D006801:Humans; D007564:Japan; D008024:Ligands; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D009154:Mutation; D010766:Phosphorylation; D017434:Protein Structure, Tertiary; D011799:Quinazolines / Q000627:therapeutic use*; D017384:Sequence Deletion; D012907:Smoking; D016896:Treatment Outcome; D014481:United States
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D008024:Ligands; D011799:Quinazolines; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D000077156:Gefitinib